Beta-amyloid (Ab) in the brain is a major factor involved in Alzheimer's disease (AD) that results in severe memory deficit. Our recent studies demonstrate pharmacogenetic differences in the effects of inhibitors of cathepsin B to improve memory and reduce Ab in different mouse models of AD. The inhibitors improve memory and reduce brain Ab in mice expressing the wild-type (WT) b-secretase site of human APP, expressed in most AD patients. However, these inhibitors have no effect in mice expressing the rare Swedish (Swe) mutant amyloid precursor protein (APP). Knockout of the cathepsin B decreased brain Ab in mice expressing WT APP, validating cathepsin B as the target. The specificity of cathepsin B to cleave the WT b-secretase site, but not the Swe mutant site, of APP for Ab production explains the distinct inhibitor responses in the different AD mouse models. In contrast to cathepsin B, the BACE1 b-secretase prefers to cleave the Swe mutant site. Discussion of BACE1 data in the field indicate that they do not preclude cathepsin B as also being a b-secretase. Cathepsin B and BACE1 could participate jointly as b-secretases. Significantly, the majority of AD patients express WT APP and, therefore, inhibitors of cathepsin B represent candidate drugs for AD.
Introduction
Alzheimer's disease (AD) results in severe memory loss resulting from age-related neurodegeneration in the brain, mainly caused by accumulation of neurotoxic b-amyloid (Ab) peptides. The majority of AD patients are afflicted with sporadic AD that is not linked to genetic mutations (Blennow et al., 2006; Turner, 2006) . A smaller portion of AD patients possess familial forms of AD with inherited genetic mutations, particularly mutations of amyloid precursor protein (APP) and presenilins that result in increased Ab production and memory deficit when overexpressed in transgenic mouse models of AD (Price and Sisodia, 1998; Masliah and Rockenstein, 2000; Dodart et al., 2002) . Development of effective therapeutic agents to improve memory in AD is essential for the increasing numbers of AD patients who are becoming afflicted as the aged population grows.
A promising therapeutic approach for AD is to develop drugs which reduce the production of brain Ab peptides because their abnormal accumulation is thought to be a major factor in causing the disease. Ab peptides are produced from APP by proteolytic cleavages at the b-secretase and g-secretase sites. The majority of AD patients express wild-type (WT) APP, but a few families express APP containing mutations at those sites, which results in Ab accumulation and onset of the disease. Because the mutant APP forms produce more Ab, mutant APP forms have often been used in developing animal models to identify potential AD therapeutics. However, because most AD patients express WT APP, it is essential to investigate drug candidates in models expressing WT APP because Ab production from the different mutant APP form could differ and affect drug development strategies.
In fact, the dramatically different effects of inhibition of the cysteine protease cathepsin B on memory deficit and brain Ab in animal models expressing WT APP versus those expressing APP containing the Swedish (Swe) mutant b-secretase site of APP (Hook et al., 2008a) demonstrate the importance of evaluating the different AD animal models. Notably, genetic deletion of cathepsin B in transgenic mice expressing human WT APP results in significant reduction of brain Ab but has no effect in mice expressing Swe APP (Hook et al., 2009) . These data suggest the importance of investigating potential differences in processing of WT APP compared with mutant APP (Chow et al., 2010) .
This review explains the basis of the novel pharmacogenetic features of inhibitors to cathepsin B as being a result of the unique cleavage specificity of cathepsin B for the WT b-secretase site of APP, but not the Swe mutant b-secretase site. These new findings about cathepsin B suggest that it may participate as a b-secretase. Together with findings in the field showing that BACE1 participates in Ab production as a b-secretase activity (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000; Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001) , cathepsin B might function with BACE1 in Ab production. Significantly, the pharmacogenetic properties of the class of molecules that inhibit cathepsin B predicts that such inhibitors might be therapeutically effective for the majority of AD patients. The emerging role of cathepsin B as a drug target for AD could benefit future development of therapeutic agents for AD. Significant results show that inhibitors of cathepsin B improve memory and reduce Ab in transgenic mice expressing human APP with the WT b-secretase site, expressed in the London APP mouse model of AD (Hook et al., 2008a) . Administration of small molecule inhibitors of cathepsin B, CA074Me and E64d, both resulted in substantial improvement in memory deficit in the London AD mouse model, assessed by the Morris water maze memory test that measures latency time to swim to a hidden platform ( Figure 1A) . Notably, the reduced latency time after inhibitor treatment indicates substantial improvement in memory, which approached that of normal mice. The effectiveness of the inhibitors to improve memory is also indicated by the reduction in distance traveled to the hidden platform ( Figure 1B) .
Pharmacogenetic differences in drug response
The inhibitor treatment reduced amyloid plaque load in brain, indicating that the compounds reduced a neuropathological hallmark of AD (Hook et al., 2008a) . Furthermore, the CA074Me and E64 inhibitors substantially reduced both Ab40 and Ab42 levels in brain (Figure 2A,B) . The CA074Me and E64 inhibitors also reduced brain levels of C-terminal b-secretase fragment (CTFb; Figure 3A ) derived from APP by b-secretase processing. Importantly, mice remained healthy after inhibitor treatment. These novel results demonstrate the in vivo effectiveness of these inhibitors of cathepsin B to improve memory deficit with reduction in brain Ab peptides and amyloid plaque load in the London APP mouse model of AD expressing human APP with the WT b-secretase site.
No effect in Swe mutant APP mice treated with inhibitors of cathepsin B
By contrast, distinct pharmacogenetic differences in inhibitor response was observed in the Swe mutant APP mouse model of AD (Hook et al., 2008a) , compared with the substantive effects on memory improvement in the London AD mice expressing APP with the WT b-secretase site. Transgenic mice expressing human Swe mutant APP have been utilized as a mouse model of AD (Hsiao et al., 1996; Price and Sisodia, 1998; Masliah and Rockenstein, 2000; Selkoe and Schenk, 2002) . The Swe APP possesses the mutant Asn-Leu residues at the b-secretase cleavage that differs from the WT sequence of Lys-Met at that site (Citron et al., 1992) .
Most interestingly, administration of the inhibitors of cathepsin B, CA074Me and E64d to Swe mutant mice (Swe mutation in the London APP mice, i.e., Swe/London APP mice) resulted in no effect on memory deficit in the Swe mutant APP mice, as measured by the Morris water maze test of latency time and distance traveled to reach the hidden platform (Figure 1C,D; Hook et al., 2008a) . Furthermore, inhibitors resulted in no change in brain levels of Ab40 and Ab42 ( Figure 2B ,C), or CTFb ( Figure 3B ) in mice with the Swe mutation of APP (Swe/London APP mice).
The effectiveness of inhibitors in AD mice expressing the WT b-secretase site of APP is relevant to the majority of AD patients These novel results demonstrate the unique pharmacogenetic features of the CA074Me and E64d inhibitors to improve memory deficit and reduce brain Ab in genetic models of AD expressing human APP with the WT b-secretase site. Moreover, these cathepsin B inhibitors reduce brain Ab in normal guinea pigs (Hook et al., 2007a,b) , indicating that these inhibitors are effective in these animals expressing WT APP with production of endogenous levels of Ab. Significantly, because the majority of the AD population expresses WT APP, the effectiveness of these inhibitors to reduce Ab generated from APP with the WT b-secretase site are relevant to the human AD disease condition.
Validation of the cathepsin B target by in vivo gene knockout studies
The CA074Me inhibitor enters cells and is then converted by esterases to CA074, a selective inhibitor of cathepsin B (Towatari et al., 1991; Yamamoto et al., 1992) . Therefore, the effectiveness of CA074Me to improve memory deficit and reduce Ab in the London APP mouse model of AD implicates a role for cathepsin B as the candidate inhibitor drug target. To confirm the predicted role of cathepsin B for Ab production and memory function, the effects of cathepsin B gene knockout on Ab production was investigated (Hook et al., 2009) .
Knockout of the cathepsin B gene in mice expressing human WT APP results in substantial decrease of Ab40 and Ab42 in brain ( Figure 4A,B) . The cathepsin B knockout Results from the original study of Hook et al. (2008a) are summarized in this Figure. (A,B) Inhibitors of cathepsin B improve memory deficit in mice expressing human APP with the WT b-secretase site. APP mice (12 months old) that express human APP with the WT b-secretase site and the London mutation V717I near the g-secretase site (known as London APP mice), representing a mouse model of AD, were treated with inhibitors of cathepsin B. The inhibitors CA074Me and E64d were administered into brains by osmotic minipump (ALZET minipump) at a rate of 0.25 ml/h of 1 mg/ml inhibitor in saline with 1.5% DMSO, corresponding to an estimated dose rate of 0.006 mg/day or 0.013 mg/day-g brain weight. After 28 days of continuous infusion of inhibitor or control saline, memory function was assessed by the Morris water maze test. Inhibitors resulted in improved memory as shown by the shorter latency time (A) for mice to swim to a hidden platform after pretraining, and the shorter distance traveled to reach the platform (B) (Hook et al., 2008a) . The dotted line indicates the latency time of normal mice that do not express human APP. Statistical significance for improved memory is indicated by ***p-0.0001 (Student's t-test), and for reduced distance traveled **p-0.0001. (C,D) Inhibitors of cathepsin B have no effect in mice expressing human APP with the rare Swe mutant b-secretase APP site. London mice expressing human APP with the Swe mutant bsecretase site of APP (known as Swe/London APP mice) were treated with inhibitors of cathepsin B as described for panels (A) and (B), and memory was assessed by the Morris water maze test. Results showed that these inhibitors resulted in no change in latency time (C) and no change in distance traveled by the mice to the platform (D) evaluated by the Morris water maze memory test. mice also showed a significant decrease in brain levels of CTFb derived from APP ( Figure 5A ), suggesting inhibition of b-secretase activity. By contrast, knockout of cathepsin B in mice expressing human APP with the rare Swe and Indiana (Ind) mutations had no effect on Ab levels in the brain ( Figure 4C ,D), and had no effect on CTFb ( Figure 5B ). The different effects of cathepsin B gene knockout to reduce Ab in mice expressing human WT APP, but not in the genetic variant of mice expressing APP with the Swe mutation, shows that the genetic animal model affects the outcomes of cathepsin B function in Ab production.
Other studies have confirmed the lack of effect of cathepsin B knockout on Ab in mice expressing APP with the Swe mutation (Mueller-Steiner et al., 2006) . However, the Mueller-Steiner studies did not examine effects of cathepsin B knockout in mice expressing WT APP. We show the contrasting difference in effectiveness of cathepsin B gene knockout to reduce Ab in mice expressing WT APP, but not Swe mutant APP mice (Hook et al., 2009) .
Furthermore, gene silencing of cathepsin B by siRNA in normal WT hippocampal brain neurons (in primary culture) reduces the amount of Ab in the regulated secretory pathway (Klein et al., 2009 ). These studies also showed that the CA074Me inhibitor reduces Ab in the regulated secretory pathway of rat hippocampal neurons, indicating a role for cathepsin B in Ab production.
These data from multiple groups validate cathepsin B as a target for development of drug inhibitors to lower Ab in the majority of AD patients expressing WT APP. Hook et al., 2005) . Further, the question of whether cathepsin B cleaves the Swe mutant b-secretase site was assessed with the substrate Z-Val-MCA (mutant residues are Asn-Leux underlined) that mimics the Swe mutant site ( Figure 6A ). Significantly, cathepsin B showed clear preference for cleaving the WT b-secretase substrate, and essentially no activity for the Swe mutant b-secretase substrate ( Figure 6B ). The distinct preference of cathepsin B for the WT b-secretase site is indicated by its high catalytic efficiency represented by its k cat /K m value of 3.17=10 5 M -1 s -1 (Hook et al., 2008a,b) , indicating an active enzyme.
Analyses with longer peptide substrates also show that cathepsin B cleaves the WT b-secretase site (Bohme et al., 2008; Hook et al., 2002) . The endogenous cathepsin B purified from Ab-containing secretory vesicles was found to cleave the WT b-secretase site of the peptide substrate SVKMxDAEF (arrow shows b-secretase site) (Hook et al., 2002) . Furthermore, cathepsin B cleaves the internally quenched fluorescent peptide substrates that contain the WT b-secretase site within the RE(Edans)EVKMxDAEFK (Dabcl)R-NH 2 substrate (Bohme et al., 2008) . These are typical long peptide substrates utilized to evaluate cleavage of the b-secretase site by b-secretases (Sinha et al., 1999; Yan et al., 1999; Hook et al., 2002) .
The selectivity of cathepsin B cleavage for the WT b-secretase site is consistent with the finding that inhibitors of cathepsin B administered to mice expressing APP with the WT b-secretase site result in reduction of CTFb and Ab (Hook et al., 2008a) . However, because cathepsin B does not cleave the Swe mutant b-secretase site of APP, inhibitors of cathepsin B do not inhibit production of Ab generated the Swe mutant APP (Hook et al., 2008a) .
The cathepsin B knockout studies validate this cysteine protease as a candidate drug target for inhibitors to reduce Ab in brain, indicating that inhibitors of cathepsin B can reduce Ab. Indeed, the CA074 and E64c inhibitors of cathepsin B in their cell permeable forms (CA074Me and E64d which are converted by intracellular esterases to CA074 and E64c) effectively reduce Ab40 and Ab42 levels in vivo (Hook et al., 2008a) . The CA074 compound selectively inhibits cathepsin B (Towatari et al., 1991) , and E64c inhibits cysteine proteases (Tamai et al., 1986) . Notably, these inhibitors significantly improved memory function (Hook et al., 2008a) , as described earlier in this review. Furthermore, the CA074 and E64c inhibitors do not affect BACE1 activity that functions as b-secretase (Table 1 ). The compounds CA074 and E64c, at 0.1 or 1.0 mM, do not affect recombinant BACE 1 activity (Table 1 ) Thus, the lack of the effects of these inhibitors on BACE 1 in vitro indicate that the inhibitors in vivo have no effect on BACE 1. Thus, direct inhibition of cathepsin B activity by the selective inhibitor CA074 (CA074 generated intracellularly from CA074Me that was administered to the animal) results in reduced brain Ab (Hook et al., 2008a) .
Clearly, the selectivity of cathepsin B for the WT (rather than the Swe mutant) b-secretase site of APP provides the basis for the pharmacogenetic differences in the effectiveness of inhibitors to cathepsin B to reduce Ab and improve memory in transgenic mice expressing human APP with WT, but not in mice expressing the Swe mutant site of APP. Because the majority of AD patients express the WT b-secretase site of APP, cathepsin B is relevant for production of Ab in most AD patients.
Neurobiology of cathepsin B for Ab production in the regulated secretory pathway of neurons
Ab peptides are secreted from neurons which leads to accumulation of extracellular Ab in amyloid plaques in brains of AD patients (Price and Sisodia, 1998; Hardy and Selkoe, 2002; Selkoe and Schenk, 2003) . The Ab secretory process is an integral component of the disease process (illustrated in Figure 7A ). Neurons possess two distinct secretory pathways consisting of: (1) ). These results were originally reported by Hook et al. (2009). 7A) (Gumbiner and Kelly, 1982; Lodish et al., 1999) . Investigation of Ab secretion has revealed its secretion from the major regulated secretory pathway, and a portion of Ab is secreted from the basal constitutive secretory pathway (Nitsch et al., 1992 (Nitsch et al., , 1993 Jolly-Tornetta et al., 1998; Hook et al., 2002 Hook et al., , 2005 .
Direct comparison of the relative amounts of Ab secreted from these two secretory pathways in neuronal-like chromaffin cells (Hook et al., 2002 (Hook et al., , 2005 revealed that a major portion of Ab is secreted from the regulated secretory pathway. Stimulation of the regulated secretory pathway by nicotine or KCl depolarization resulted in prominent increase in Ab secretion ( Figure 7B ). However, basal unstimulated secretion of Ab represented a smaller portion of secreted Ab. Furthermore, studies in rat hippocampal neurons also demonstrate regulated secretion of Ab peptides (Klein et al., 2009 ). These findings indicate that a major portion of secreted Ab is present in the regulated secretory pathway that provides extracellular Ab that accumulates in AD brains.
Based on knowledge that the regulated secretory pathway provides a major portion of secreted extracellular Ab, regulated secretory vesicles that contain Ab and APP (Efthimiopoulos et al., 1996; Tezapsidis et al., 1998) should also have b-secretase activity for Ab production. Therefore, protease activity assayed with the Z-Val-Lys-Met-xMCA substrate, mimicking the WT b-secretase site (indicated by arrow), was purified from regulated secretory vesicles isolated from neuronal-like chromaffin cells (Hook et al., 2002) . Identification of the purified protease by mass spectrometry indicated cathepsin B as the candidate b-secretase (Hook et al., 2005) . Notably, inhibitors of cathepsin B reduced production of Ab in the isolated regulated secretory vesicles (Hook et al., 2005) . These inhibitors of cathepsin B also reduced production of Ab in the regulated secretory pathway of hippocampal neurons (rat) (Klein et al., 2009 ). However, these inhibitors had no effect on Ab in the constitutive secretory pathway. These findings indicate the key role of cathepsin B in Ab production in the regulated secretory pathway of neurons.
Participation of cathepsin B in production of Ab via cleavage of the WT b-secretase site of APP in the regulated secretory pathway of neurons
Ab production in regulated secretory vesicles by cathepsin B has been demonstrated in several neuronal and animal model systems consisting of neuronal systems in culture and in animal models from bovine, guinea pig, mouse, and rat (summarized in Table 2 ) (Hook et al., 2005 (Hook et al., , 2007a (Hook et al., ,b, 2008a (Hook et al., ,b, 2009 Bohme et al., 2008; Klein et al., 2009 ). These studies support the hypothesis that cathepsin B might produce Ab from APP via b-secretase activity in the regulated secretory pathway, but not the constitutive secretory pathway. CTFb levels in brains of cathepsin B knockout mice, compared with mice with normal cathepsin B gene expression, were not changed in mice that express mutant human APP with the Swe mutant b-secretase site and the Ind mutation near the g-secretase site (Swe/Ind APP mice). Quantitation of relative CTFb levels in brain was assessed by densitometry of Western blots that detected CTFb (approx. 12 kDa). These results were originally reported by Hook et al. (2009). Furthermore, cathepsin B in regulated secretory vesicles cleaves the WT b-secretase site of APP to produce Ab. Inhibitors of cathepsin B are hypothesized to reduce Ab by lowering its production in the regulated secretory pathway through inhibition of b-secretase activity.
BACE1 b-secretase data do not preclude cathepsin B as also being a b-secretase
There has been much investigation in the field on the aspartyl protease BACE1 that functions as b-secretase (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000; Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001) . With recent data indicating that cathepsin B is involved in Ab production (Hook et al., 2005 (Hook et al., , 2007a (Hook et al., ,b, 2008a (Hook et al., ,b, 2009 Bohme et al., 2008; Klein et al., 2009 ), the combined findings in the field indicate that cathepsin B and BACE1 function jointly in Ab production. Analyses of the BACE1 studies indicate that they are consistent with the hypothesis for joint roles of these proteases for Ab production, explained in this section.
BACE1 prefers to cleave the Swe mutant b-secretase site, rather than the WT b-secretase site of APP The Swe mutant APP possesses alterations of two amino acids at the b-secretase site that leads to increased Ab; this rare mutation is present in an extended family (Citron et al., 1992) . The Swe mutation provided rationale in the field to search for b-secretase using a substrate with the Swe mutation, leading to identification of BACE1 (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000) . These studies showed that although BACE1 readily cleaves the Swe b-secretase site, it has poor efficiency for cleaving the WT b-secretase site.
BACE1 activity for the WT b-secretase substrate is extremely low, cleaving it with only low k cat /K m values of 40-60 M -1 s -1 (Lin et al., 2000; Shi et al., 2001) , whereas proteases acting on relevant substrates have k cat /K m values that range between tens of thousands to a few millions (Dunn and Hung, 2000) . For BACE1 to obtain a k cat /K m that approaches that of other proteases for their substrates, seven out of eight amino acid residues in the WT b-secretase peptide substrate must be modified (Turner et al., 2001) . By contrast, cathepsin B has a k cat /K m for cleaving WT b-secretase site substrates of 317 000 M -1 s -1 (Hook et al., 2008a,b) . These kinetic properties demonstrate the low effectiveness of BACE1 for cleaving the WT b-secretase site, compared with the highly effective cathepsin B cleavage of WT b-secretase site substrates.
The difference in effectiveness of BACE1 to cleave the Swe mutant compared with the WT b-secretase sites is consistent with knowledge of the importance of amino acid residues adjacent to protease cleavage sites. The Swe mutation substitutes the neutral asparagine residue for the positively charged lysine residue at the key P2 protease-substrate recognition site. The different uncharged compared with the charged residue at the P2 position is likely to be crucial for recognition of the cleavage site by proteases (Barrett et al., 1998; Siegel et al., 1999; Hook et al., 2008b) . Such protease cleavage properties can explain the preference of BACE1 for the Swe mutant b-secretase site compared with the WT site.
BACE1 knockout in Swe APP expressing mice
Because BACE1 cleaves the Swe mutant APP, investigators have utilized transgenic mice expressing human Swe mutant APP as an AD model for studies of BACE1 gene knockout. Indeed, a study by Luo et al. (2001) showed that knockout of BACE1 reduced brain Ab and CTFb, which provides support for involvement of BACE1 as the b-secretase for the Swe mutant APP. These BACE1 studies, however, do not rule out a role for cathepsin B in production of Ab from WT APP. The Swe mutation is indicated by the mutant Asn-Leu residues that substitute for the normal Lys-Met residues adjacent to the b-secretase cleavage site. These WT and Swe mutant peptide sequences were utilized for design of protease cleavage site specific assays for the WT b-secretase site and the respective Swe mutant site, as shown in (B). (B) Cathepsin B displays specificity for cleaving the WT b-secretase site, but not the Swe mutant b-secretase site. A cleavage site specific protease assay was designed to detect cleavage at the WT b-secretase site utilizing the Z-Val-Lys-Met-xMCA (Z-V-K-M-MCA) substrate that mimics the WT cleavage site. In parallel, the substrate Z-Val---xMCA was utilized to assay protease cleavage at the Swe mutant site (Swe mutant Asn Leu residues are underlined). These substrates provided cleavage site-specific protease assays for cleavage of the WT or Swe mutant sites. Assay of cathepsin B with these substrates provided comparison of its high specific activity (pmol AMC/min/mg enzyme) for the WT substrate, and essentially no activity with the Swe mutant substrate. These results were originally reported by Hook et al. (2008a) . Table 1 Inhibitors of cathepsin B have no effect on BACE 1 activity.
Inhibitor BACE 1 activity, % of control 
-test).
The activity of purified recombinant BACE 1 (R&D Systems, Minneapolis, MN, USA) was evaluated in the presence of inhibitors of cathepsin B consisting of CA074 that selectively inhibits cathepsin B and E64c that inhibits cysteine proteases; each inhibitor was tested at 0.1 mM and 1.0 mM. The inhibitors of cathepsin B showed no effects on BACE 1 activity, assayed with the substrate
However, BACE 1 activity was nearly completely inhibited by the statine BACE 1 inhibitor (Sinha et al., 1999) . Effects of inhibitors on BACE 1 activity are expressed as percent of control (no inhibitor), indicated by the mean of replicate assays.
Beta-secretase activity in BACE1 knockout mice
Seemingly convincing evidence for BACE1 as the brain b-secretase by a study by Roberds et al. (2001) found that BACE1 knockout mice completely lack brain b-secretase activity. However, a closer reading of the study indicates that the b-secretase assays contained E64, a potent inhibitor of cathepsin B. Thus, the assay condition with the E64 inhibitor made it impossible to detect the cysteine protease activity of cathepsin B. Therefore, the assay conditions by Roberds do not rule out cathepsin B as having b-secretase activity.
Ab production and secretion in neurons of BACE1 knockout mice
The Roberds study found lower Ab levels in media from cultured brain neurons obtained from BACE1 knockout mice which implicated participation of BACE1 (Roberds et al., 2001) . However, the Ab in 'conditioned medium' indicates constitutive secretion of Ab because the neurons were not stimulated to secrete. The Roberds study did not measure regulated secretion of Ab and, therefore, their data do not rule out participation of cathepsin B. The same analysis applies to a study by Cai et al. (2001) , which also found reduced Ab in conditioned medium secreted from neurons from BACE1 knockout mice, indicating a role for BACE1 in the constitutive secretory pathway. Again, the study did not address regulated secretion and, therefore, does not rule out cathepsin B participation in Ab production in the regulated secretory pathway.
BACE1 and Ab production from normal compared to super high levels of APP: relation to AD patients expressing physiological normal levels of APP
The brains of AD patients possess physiologically normal levels of APP (Hirata-Fukae et al., 2008) . Therefore, several studies have investigated the effects of BACE1 on Ab production from endogenous, normal levels of WT mouse brain APP, which express APP containing the human WT b-secretase site sequence. A study by Matsuoka and colleagues showed that homozygous knockout of the BACE1 gene (BACE1 -/-) in WT mice essentially eliminated all of the mouse brain Ab1-40 and reduced Abx-40 by approximately 25% (Nishitomi et al., 2006) . However, that paper also shows that heterozygous BACE1 gene deletion (BACE1 -/q ) has no effect on mouse brain Ab. A more recent study by the same (A) Regulated and constitutive secretory pathways for secretion of Ab from neurons. APP processing occurs during axonal transport from the neuronal cell body to nerve terminals where Ab is secreted to the extracellular domain. Within neurons, APP processing occurs via proteolysis by b-secretase and g-secretase proteases to generate Ab40 and Ab42. Secretion of Ab occurs by the major regulated secretory pathway that provides activity-stimulated secretion of Ab (Nitsch et al., 1992 (Nitsch et al., , 1993 Jolly-Tornetta et al., 1998; Hook et al., 2002 Hook et al., , 2005 . Secretion of Ab also occurs via basal, constitutive secretion that provides a lesser portion of extracellular Ab. Secreted extracellular Ab peptides accumulate as oligomers and aggregates in amyloid plaques, and cause loss of memory in AD. (B) Reduction of Ab production in the regulated secretory pathway by CA074Me inhibitor of cathepsin B. Neuronal-like chromaffin cells were treated with the inhibitor CA074Me (50 mM) for 18 h. Regulated secretion (R) was induced by KCl (50 mM) for 15 min, and Ab40 was measured in secretion media. Secretion by the regulated secretory pathway (R) is represented by KCl-stimulated secretion. Basal secretion (no KCl) represents secretion from the constitutive secretory pathway (C). Results show significant reduction by CA074Me of Ab secreted from the regulated secretory pathway, with *p-0.05 (Student's t-test). These results were originally reported by Hook et al. (2005). group showed that overexpression of BACE1 in WT mice has no effect on mouse brain Ab levels, which led that group to conclude that BACE1 'has minimal effect on the level of endogenous Ab' and that 'other factors must be involved in modulation of Ab production in adult and aging brain' (Hirata-Fukae et al., 2008) . Taken together, these data suggest that levels of BACE 1 protein appear to not be rate-limiting in the production of Ab peptides. These results raise questions as to the role of BACE1 in producing Ab from the physiologically normal levels of WT APP in AD patients. Thus, these data open the possibility that another protease, such as cathepsin B, might also be involved in Ab production.
Another study showed that at super high levels of APP expression in transgenic mice, BACE1 gene knockout resulted in decreased brain Ab levels (McConlogue et al., 2007) . The McConlogue study used PDAPP transgenic mice that express extremely high levels of APP. These findings indicate that BACE1 can function with very high, non-physiological levels of APP. It is known that protease enzyme activities are dependent on substrate levels (Voet and Voet, 2004; Hook et al., 2008b) . Thus, the data in the field suggest involvement of BACE1 in processing high levels of APP substrate, but data suggest that BACE1 has lesser effects on normal physiological levels of APP for Ab production. (Hook expressing WT expressing (bovine) in primary culture (rat) (Klein et al., et al., 2007a,b) hAPP, brain hAPPLon, brain (Hook et al., 2005) (Hook et al., 2007a) . These data indicate that cathepsin B functions at normal levels of APP for Ab production. Furthermore, knockout of the cathepsin B gene in mice expressing human APP with the WT b-secretase site results in reduced brain Ab and substantial improvement in memory deficit (Hook et al., 2008a) .
Despite the fact that BACE1 was discovered as a b-secretase more than a decade ago, combined with the expenditure of extraordinary resources and effort to develop BACE1 inhibitors, no BACE1 inhibitor is known to be clinically effective to reduce brain Ab in patients. There is clearly a crucial need for effective AD therapeutic agents. The inhibitors of cathepsin B are effective Ab lowering agents that result in improved memory in AD mouse models. It is, thus, essential to develop such inhibitors of cathepsin B as candidate therapeutic agents for AD patients.
An alternative, but unlikely, hypothesis is that cathepsin B activates a-secretase An alternative effect of inhibitors of cathepsin B is that they might stimulate the a-secretase pathway and thereby reduce Ab. Alpha-secretase cleaves within the Ab domain of APP and thus, precludes formation of Ab. Although this might be possible, it is not a probable mechanism. The hypothesis that cathepsin B possesses b-secretase activity is the more probable means by which the cathepsin B inhibitors reduce Ab, as explained here.
The inhibitors of cathepsin B increased brain levels of sAPPa derived from APP by a-secretase cleavage (Hook et al., 2008a) . This observation can be explained by the inhibitor-induced decrease in b-secretase activity, documented by decreased levels of CTFb derived from APP by b-secretase, which could result in a larger portion of APP available for a-secretase cleavage. Alternatively, the inhibitors could increase a-secretase activity, but this alternative is highly unlikely because of the fact that cathepsin B was initially identified based on its b-secretase activity for purification, and not a-secretase activity (Hook et al., 2005) . Thus, it would be pure serendipity that the protease found through its b-secretase activity also activates an entirely different protease. Although not impossible, this would not be expected and thus improbable. Rather, the more straightforward explanation is that cathepsin B performs the b-secretase activity that was the basis for its purification (Hook et al., 2005) .
Studies of BACE1 also show that sAPPa is increased owing to deleting or inhibiting this b-secretase (Nishitomi et al., 2006) . The study concluded that the sAPPa increase is probably owing to a reduction in b-secretase activity causing more APP substrate to be available for a-secretase production of sAPPa. Similarly, we also explain that the increase in sAPPa resulting from cathepsin B inhibition or deletion might be owing to reducing b-secretase activity causing increased APP for a-secretase cleavage (Hook et al., 2008a) . Overall, the cathepsin B data support the hypothesis for cathepsin B participating as a b-secretase for Ab production.
Conclusion: the majority of AD patients express WT APP and are predicted to respond to inhibitors of cathepsin B as candidate therapeutic agents
Cathepsin B is a valid target for therapeutic reduction of brain Ab, as indicated by the data that inhibitors of cathepsin B result in effective improvement in memory deficit and reduction of brain Ab in mice expressing human APP with the WT b-secretase site. The pharmacogenetic differences in drug response in AD mouse models with the WT or Swe mutant b-secretase site indicate the importance of genetic features for drug efficacy. Notably, because the majority of AD patients express WT APP, and cathepsin B has specificity for the WT b-secretase site, cathepsin B is a valid drug target for AD. These findings suggest that development of cathepsin B inhibitors could be useful for novel therapeutic strategies in AD.
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